share_log

信達生物：截至2024年3月31日止月份之股份發行人的證券變動月報表

INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024

香港交易所 ·  Apr 8 04:35
Summary by Moomoo AI
信達生物製藥於2024年3月31日提交了最新的證券變動月報表，該報表顯示公司普通股股份數目在3月份保持不變，總數為5,000,000,000股，法定/註冊股本總額為50,000美元。報告同時指出，已發行股份有所增加，本月底結存為1,622,682,897股，較上月增加100,000股。此外，股份期權計劃方面，首次公開發售前股份獎勵計劃已行使100,000股份期權，而首次公開發售後僱員持股計劃則有448,428股份期權被註銷。本月內因行使期權所得資金總額為231,081.1港元。信達生物製藥確認所有證券發行均已獲得董事會批准，並符合香港聯合交易所有限公司證券上市規則的要求。
信達生物製藥於2024年3月31日提交了最新的證券變動月報表，該報表顯示公司普通股股份數目在3月份保持不變，總數為5,000,000,000股，法定/註冊股本總額為50,000美元。報告同時指出，已發行股份有所增加，本月底結存為1,622,682,897股，較上月增加100,000股。此外，股份期權計劃方面，首次公開發售前股份獎勵計劃已行使100,000股份期權，而首次公開發售後僱員持股計劃則有448,428股份期權被註銷。本月內因行使期權所得資金總額為231,081.1港元。信達生物製藥確認所有證券發行均已獲得董事會批准，並符合香港聯合交易所有限公司證券上市規則的要求。
Sinda Biopharmaceuticals filed its latest Securities Monthly Change Report on March 31, 2024, which shows that the number of ordinary shares of the company remained unchanged in March with a total of 5,000,000,000 shares and a total regulated/registered share capital of $50,000. The report also noted that issued shares increased to 1,622,682,897 shares outstanding at the end of the month, an increase of 100,000 shares compared to the previous month. In addition, 100,000 share options have been exercised under the share option plan before the IPO, and 448,428 share options have been written off in the employee holding plan after the initial public offering. The total amount of capital gained from the exercise of options during the month was HK$231,081.1. SINDA BIOPHARMACEUTICALS CONFIRMS THAT ALL SECURITIES ISSUES HAVE BEEN APPROVED BY THE BOARD AND COMPLY WITH THE REQUIREMENTS OF THE SECURITIES LISTING RULES OF THE HONG KONG STOCK EXCHANGE LIMITED.
Sinda Biopharmaceuticals filed its latest Securities Monthly Change Report on March 31, 2024, which shows that the number of ordinary shares of the company remained unchanged in March with a total of 5,000,000,000 shares and a total regulated/registered share capital of $50,000. The report also noted that issued shares increased to 1,622,682,897 shares outstanding at the end of the month, an increase of 100,000 shares compared to the previous month. In addition, 100,000 share options have been exercised under the share option plan before the IPO, and 448,428 share options have been written off in the employee holding plan after the initial public offering. The total amount of capital gained from the exercise of options during the month was HK$231,081.1. SINDA BIOPHARMACEUTICALS CONFIRMS THAT ALL SECURITIES ISSUES HAVE BEEN APPROVED BY THE BOARD AND COMPLY WITH THE REQUIREMENTS OF THE SECURITIES LISTING RULES OF THE HONG KONG STOCK EXCHANGE LIMITED.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more